Research and expenditures were delayed during the first four months of this project. Although the award became effective on Sept. 15, 1996 , the University of California, Berkeley could not formally activate it and begin to process the subcontracts to Scripps and the University of Hawaii until early December 1996. This delayed recruitment, purchasing, and equipment procurement at all three institutions. Despite this, Drs. Li and Roberts accomplished most of their major Year 1 objectives described in the proposal. Dr. Karu's laboratory moved to the main Berkeley campus in December 1996 and January 1997, and Ms. Zhao, the primary technical person on the project was on maternity leave until April 1997. Dr. Li's laboratory was also relocating and was unable to begin work on the project until early March. Computer and software problems slowed some of Dr. Roberts's work early in 1997. To compensate for these delays Dr Karu's laboratory assumed some of the Li lab's hapten and conjugate synthesis tasks from April through July, and the two labs completed virtually all of the proposed hapten synthesis for the entire project. This enabled the Karu lab to proceed with combinatorial library screening, and the Li lab was able to begin developing PAH immunoassays and residue recovery methods in Year 1, rather than wait until Year 2. Dr. Li is employing a graduate student and another postdoctoral researcher to accelerate his part of the project. The Karu lab's antibody engineering tasks can be done more efficiently in Year 2. We propose to use the unspent Year 1 funds to employ a second person to perform the unfinished tasks beginning in January 1998.
T ECHNICAL S UMMARY -Y EAR 1
OBJECTIVE: The objective of this multidisciplinary project is to use molecular biological techniques to derive a set of antibodies with useful affinities and selectivities for recovery and detection of polynuclear aromatic hydrocarbons (PAHs) in environmental and biological samples. The long-term goal is to develop immunodetection methods that will be useful in biomarker research and regulatory monitoring of PAHs.
APPROACH The aims and approaches remain the same as in the original proposal. My laboratory cloned and characterized two PAL-I-specific recombinant Fab antibodies (rFabs). We are deriving new affinities and specificities for PAHs by mutagenesis of these rFabs, and by selection of new rFabs from combinatorial phage display libraries. Dr. Qing Li's group designed and synthesized PAH haptens that were essential for my laboratory's work. Dr. Victoria Roberts's group developed molecular models that suggested the mechanism of PAH binding and predicted mutations to alter it. Dr. Li's laboratory is using the recombinant antibodies we produce to develop immunoaffinity and immunoassay methods to quantify PAHs in environmental samples.
ACCOMPLISHMENTS: (Karu Laboratorv): The major progress in Dr. Karu's laboratory is summarized below. Separate reports by Drs. Roberts and Li are appended. 0 0 PAH binding kinetics were measured by three different methods. The monoclonal antibodies (MAbs) from which we derived rFab antibodies had affinity constants and fast on-and off rates for benzolalpyrene and phenanthrene binding that are suitable for sensor applications. The rFabs had one-half to one-fourth the affinity of the parent MAbs. When compared with the MAbs, the rFab sequences had four different amino acids (including one extra glutamic acid) at the N terminus of the heavy chain variable domain, and three different amino acids at the N terminus of the light chain variable domain. These substitutions were introduced by the degenerate PCR primers used for gene amplification. Molecular modeling done by Dr. Roberts indicated that these substitutions may deform the PAH binding pocket. We are using in vitro mutagenesis to restore the original sequence. This should give the rFabs the same PAH binding affinity as the MAbs.
on the order of 103 to lo4 -in the original population of 1.2 x 1013 . Recovered phage were amplified by growth in E. coli, and depleted of antibodies that bound to the carrier proteins. Aliquots of this "PAH daughter library" were subjected to four cycles of amplification and panning with benzo[a]pyrene-6-and fluoranthene-3-haptens. This enriched the rFabs to these haptens by about 106-fold. These rFab sequences are being amplified en masse by PCR, inserted into an expression vector, and induced to express soluble rFab. Those that competitively bind benzo[a]pyrene and fluoranthene will be selected by enzyme immunoassay (EIA) SIGNIFICANCE: Despite initial delays, several of the most important goals of the project were achieved during the past year. Twenty-nine PAH haptens were synthesized, representing all of the major PAHs that are likely to be detectable by immunoassay. All were prepared using only two general synthesis schemes -a Friedel-Crafts reaction and a Wittig reaction. These could be used to prepare additional haptens, including haptens of some heterocyclic PAHs, in the same way. Procedures for recovering PAH-specific antibodies from a very large combinatorial phage display library were worked out. Sequences that bind benzo[a]pyrene and fluoranthene were enriched sufficiently to make identification of the desired rFabs by standard EIA feasible. Dr. Li's group has formatted sensitive benzo[a]pyrene specific EIAs with one of our rFabs. They are now able to focus on making the EIA practical for use with real-world environmental samples.
The reduced affinity of the rFabs we cloned from two hybridoma lines, apparently a consequence of using degenerate PCR primers, is likely to arise in nearly all derivations of recombinant antibodies from cells. Our experiments will test whether this artifact may be corrected by in vitro mutagenesis. The molecular modeling done by Dr. Roberts's group indicates that PAH binding involves electrostatic complementarity, as well as shape, and may be a more general mechanism for antibody, enzyme, and receptor binding of other planar hydrophobic molecules. The models predict which amino acid side chains in the antibody participate in PAH binding, and how well different PAHs fit in the site. These predictions provide a rationale for our plans to engineer the antibodies, and a theoretical basis for understanding the results of Dr. Li's assay development with different competitor haptens.
WORK PLAN FOR YEAR II (Karu laboratory):
The project will proceed essentially as described in the original proposal. Dr. Karu's laboratory will derive and characterize sets of rFabs that primarily bind to each of the nine PAH haptens. The engineering of rFabs 4D5 and l0C10, originally scheduled for Year 1, will be done in the coming year, based on the models and predictions made by Dr. Roberts's group. Several mutants of rFabs 4D5 and l0Cl0 will be constructed to test whether PAH binding is altered by changing the amino acids at the Ntermini, or by changing the arginine and lysine on either side of the binding pocket. rFabs with useful properties will be scaled up, purified, and provided to Dr. Li's group for multianalyte immunoassay development. Dr. Roberts's group will build structure models to reveal similarities or differences in PAH binding by various rFabs.
Engineered Antibodies for Monitoring of Polynuclear Aromatic Hydrocarbons
Year-l Progress Report from Department of Environmental Biochemistry, University of Hawaii Report period: 10/l/1996 to 9/31/1997 Q.X. Li 1. Year-l Objectives: a. Synthesis, purification, and characterization of haptens. b. Conjugation of haptens to enzymes, carrier proteins and solid phases. c. Initial development of immunoaffinity and immunoassay methods.
Approach:
We have actively communicated with Drs. Karu (UC-Berkeley) and Roberts (The Scripps Research Institute) and their research groups. Hapten design was assisted by Dr. Roberts's computer modeling and interpretation of the binding site configuration of mAb 10Cl0.
3.Accomplishments:
a. Synthesis, purification, and characterization of haptens. We synthesized a library of 20 PAH haptens (Figure 1 ). These are derivatives of naphthalene, anthracene, phenanthrene, pyrene, fluoranthene, chrysene, fluorene and benzo [a] pyrene with spacers having a carboxylic acid terminus. The haptens were conjugated with various proteins and enzymes by standard methods. These conjugates are being used by Dr. Karu's laboratory to select recombinant Fab antibodies (rFabs) from a combinatorial phage display library, and by my laboratory to develop immunoassays for PAHs in environmental samples. b. Initial development of immunoaffinity and immunoassay methods. Assays are being developed using PAH-specific monoclonal antibody (mAb) 10Cl0 and rFab 10C10. Figure 2 shows some of the conjugates that we are using to develop benzo[a]-pyrene immunoassays. We found that indirect competition EIAs could be performed using many of the 20 PAH-protein conjugates as competitors (Table below) . We are now testing how these different coating antigens affect selectivity for PAHs. 5. Work Plan: We will continue our effort on development, validation and application of immunochemical methods for real world samples. Our year-2 objectives are: a. Immunoaffinity methods for recovery and cleanup of PAH residues b. Begin adapting solid phase extraction and supercritical fluid extraction for PAH sample preparation c. Formatting and validation of multi-analyte PAH immunoassay d. Synthesis and testing of candidate photoaffinity analogs of PAHs.
6. Personnel Involved: Dr. Q.X. Li (30% FTE, no salary support) is responsible for all work conducted at the University of Hawaii. This project supports Dr. K. Li (100% FTE, a post-doctoral fellow), Dr. R. Chen (l5%FTE, a junior chemist) and Mr. Steven Thomas 50% FTE, a graduate student). Ms. Mei Liu (50% FTE), a graduate student supported by a teaching assistantship from Department of Chemistry, University of Hawaii at Manoa also works on this project.
